Forcing a single clinical supply model across APAC creates delays, costs, and regulatory risks. This presentation addresses regional complexities through flexible strategies and local collaboration.
- Model Selection: Evaluating central, regional, and hybrid supply frameworks.
- Streamlined Logistics: Bridging gaps between sourcing, compliance, and local distribution.
- Risk Mitigation: Overcoming cross-border bottlenecks and critical documentation challenges.
- Strategic Value: Balancing speed, cost, and long-term partner alignment over transactional relationships.
在亚太地区强推单一的临床供应链模型会导致延误、高昂成本和合规风险。本演讲将通过灵活的战略与本地化合作，探讨并解决这些区域复杂性问题。
- 模式选择：评估集中式、区域式以及混合式的供应链架构。
- 高效物流：消除采购、合规与本地分销之间的断层。
- 风险缓解：克服跨境瓶颈与关键文件审查带来的挑战。
- 战略价值：权衡速度与成本，建立长期的伙伴协作，而非单纯的业务交易
China’s pharmaceutical innovation stands at a pivotal inflection point. After a decade of explosive growth, the industry is navigating a period of “capital winter,” intense policy-driven competition, and a strategic shift from the pursuit of quantity to the mandate of quality. However, this pressure is also a catalyst, forcing a clear-eyed re-evaluation of the path forward. Today, China is not just a vast clinical trial hub or a manufacturing powerhouse; it is defining its ambition to become a “world new drug creation center” by 2035.
中国医药创新正处在关键转折点。经历十年的爆发式增长后，行业经历了“资本寒冬”、政策驱动的激烈竞争，以及从追求数量转向强调质量的战略变化。在这种压力下，行业对未来发展有了更清醒的认识。现在，中国不再只是庞大的临床试验中心或制造强国；它正在定义到 2035 年成为“世界新药创制中心”的雄心。
- The “Innovation Pivot”: From Fast-Follower to First-in-Class
- The “Globalization 2.0” Playbook: From BD Transactions to Enduring Value
- The “Dual Engine” of Policy: Regulatory Acceleration Meets Payment Reformation
- Convergence and Concentration: Surviving the “Great Integration”
- The Ultimate Alignment: Bridging the Pipeline to Unmet Clinical Need
- “创新转向”：从快速跟随到 First-in-Class
- “全球化 2.0”打法：从 BD 交易到持久价值
- 政策“双引擎”：监管加速与支付改革并进
- 融合与集中：在“大整合”中生存
- 终极方案：将管线与未满足的临床需求相适配
Moderator: Sarah Nightingale, APAC Principal Consultant, GlobalData
A single biopharma portfolio today may encompass a diverse mix of modalities—small molecules, monoclonal antibodies, ADCs, cell therapies, and more—each with vastly different and often contradictory supply chain requirements. This new reality demands a fundamental shift towards platform-based supply chain strategies.
- What Are We Actually Building?
- Orchestrating Complexity with Data & AI
- From Transactional Vendors to Strategic Capability Partners
- Upskilling Teams for a Multi-Modality World
如今，单一生物医药企业的研发管线可能涵盖多种不同的药物模态——小分子、单克隆抗体（单抗）、抗体偶联药物（ADCs）、细胞疗法等。这些药物对供应链的要求截然不同，甚至相互冲突。这一新现状要求供应链管理必须发生根本性转变，全面走向平台化策略。
- 我们究竟在构建什么？
- 利用数据与人工智能（AI）协调整合复杂流程
- 从传统的交易型供应商转型为战略能力合作伙伴
- 赋能团队升级，全面迎接多模态时代
